Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 37
Filtrar
1.
Clin Res Cardiol ; 2021 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-33721056

RESUMO

BACKGROUND: For patients with heart failure (HF), iron deficiency (ID) is a common therapeutic target. However, little is known about the utility of transferrin saturation (TSAT) or serum ferritin for risk stratification in decompensated HF (DHF) or the European Society of Cardiology's (ESC) current definition of ID (ferritin < 100 µg/L or TSAT < 20% if ferritin is 100-299 µg/L). We evaluated the association between these potential markers of ID and the risk of 30-day readmission for HF or death in patients with DHF. METHODS: We retrospectively included 1701 patients from a multicenter registry of DHF. Serum ferritin and TSAT were evaluated 24-72 h after hospital admission, and multivariable Cox regression was used to assess their association with the composite endpoint. RESULTS: Participants' median (quartiles) age was 76 (68-82) years, 43.8% were women, and 51.7% had a left ventricular ejection fraction > 50%. Medians for NT-proBNP, TSAT, and ferritin were 4067 pg/mL (1900-8764), 14.1% (9.0-20.3), and 103 ug/L (54-202), respectively. According to the current ESC definition, 1,246 (73.3%) patients had ID. By day 30, there were 177 (10.4%) events (95 deaths and 85 HF readmission). After multivariable adjustment, lower TSAT was associated with outcome (p = 0.009) but serum ferritin was not (HR 1.00; 95% confidence interval 0.99-1.00, p = 0.347). CONCLUSIONS: Lower TSAT, but not ferritin, was associated with a higher risk of short-term events in patients with DHF. Further research is needed to confirm these findings and the utility of serum ferritin as a marker of ID in DHF.

2.
Scand Cardiovasc J ; : 1-6, 2020 Oct 08.
Artigo em Inglês | MEDLINE | ID: mdl-33030056

RESUMO

OBJECTIVES: Serum levels of matrix metalloproteinase-12 cleaved fragment of titin (TIM), a novel circulatory biomarker specific for cardiac titin degradation, has emerged as a potential biomarker in cardiovascular diseases. In this work, we aimed to evaluate the association between TIM and maximal functional capacity assessed by the percentage of predicted peak exercise oxygen uptake (pp-peakVO2) in patients with heart failure and preserved ejection fraction (HFpEF). Design. In this post-hoc study, we included 46 stable symptomatic (New York Heart Association II-III) HFpEF patients enrolled in the TRAINING-HF study (NCT02638961). pp-peak-VO2 was calculated from baseline values. Baseline circulating levels of TIM were measured by competitive ELISA in serum from the TRAINING-HF patients. The independent association between TIM and pp-peakVO2 was evaluated by multivariate linear regression analysis. Results. The mean age of the sample was 73.8 ± 8.7 years, 56.5% were females, and 76.1% were on NYHA II. The medians of pp-peakVO2 and TIM were 60.9% (50.4-69.3), and 130.1 ng/mL (98.1-159.5), respectively. The median of NT-proBNP was 912 pg/mL (302-1826). pp-peakVO2 was significant and inversely correlated with TIM (r= -41, p = .005). In multivariate analysis, after adjusting for NYHA class, hypertension, body mass index, and glomerular filtration rate, higher TIM was significantly associated with lower pp-peak VO2 (p = .029). Conclusions. In this sample of stable and symptomatic HFpEF patients, higher serum levels of TIM identified patients with worse functional status.

4.
Rev. esp. cardiol. (Ed. impr.) ; 73(6): 463-470, jun. 2020. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-197621

RESUMO

INTRODUCCIÓN Y OBJETIVOS: La diabetes mellitus tipo 2 (DM2) es una comorbilidad común en pacientes con insuficiencia cardiaca (IC) con fracción de eyección conservada (ICFEP). Estudios anteriores han demostrado que las mujeres diabéticas tienen mayor riesgo de desarrollar insuficiencia cardiaca que los hombres. Sin embargo, el pronóstico a largo plazo de los pacientes diabéticos con insuficiencia cardiaca en función del sexo no se ha explorado ampliamente. En este estudio, nuestro objetivo fue evaluar el impacto diferencial de la DM2 en la mortalidad por todas las causas en hombres frente a mujeres con ICFEP tras un ingreso por IC aguda. MÉTODOS: Se incluyeron prospectivamente 1.019 pacientes consecutivos con ICFEP dados de alta tras un episodio de IC aguda en hospital terciario. Se empleó un análisis de regresión de Cox multivariante para evaluar la interacción entre el sexo y la DM2 con respecto al riesgo de mortalidad total a largo plazo. Las estimaciones de riesgo se expresaron como razones de riesgo (HR). RESULTADOS: La edad media de la cohorte fue de 75,6±9,5 años y 609 (59,8%) eran mujeres. La proporción de DM2 fue similar entre ambos sexos (45,1 frente al 49,1%; p = 0,211). Tras una mediana de seguimiento (intervalo intercuartílico) de 3,6 (1-4-6,8) años, 646 (63,4%) pacientes murieron. Tras ajustar por factores de riesgo, comorbilidades, biomarcadores, parámetros ecográficos y tratamiento al alta, el análisis multivariate mostró un efecto pronóstico diferencial de DM2 (valor de p para la interacción=0,007). La DM2 se asoció con un mayor riesgo de mortalidad por todas las causas en mujeres (HR=1,77; IC95%, 1,41-2,21; p < 0,001) pero no en varones (HR=1,23; IC95%, 0,94-1,61; p = 0,127). CONCLUSIONES: Tras un episodio de IC aguda en pacientes con ICFEF, la DM2 confiere un mayor riesgo de mortalidad en las mujeres. Se requieren más estudios que evalúen el impacto de la DM2 en mujeres con ICFEP


INTRODUCTION AND OBJECTIVES: Type 2 diabetes mellitus (DM2) is a common comorbidity in patients with heart failure (HF) with preserved ejection fraction (HFpEF). Previous studies have shown that diabetic women are at higher risk of developing HF than men. However, the long-term prognosis of diabetic HFpEF patients by sex has not been extensively explored. In this study, we aimed to evaluate the differential impact of DM2 on all-cause mortality in men vs women with HFpEF after admission for acute HF. METHODS: We prospectively included 1019 consecutive HFpEF patients discharged after admission for acute HF in a single tertiary referral hospital. Multivariate Cox regression analysis was used to evaluate the interaction between sex and DM2 regarding the risk of long-term all-cause mortality. Risk estimates were calculated as hazard ratios (HR). RESULTS: The mean age of the cohort was 75.6±9.5 years and 609 (59.8%) were women. The proportion of DM2 was similar between sexes (45.1% vs 49.1%, P=.211). At a median (interquartile range) follow-up of 3.6 (1-4-6.8) years, 646 (63.4%) patients died. After adjustment for risk factors, comorbidities, biomarkers, echo parameters and treatment at discharge, multivariate analysis showed a differential prognostic effect of DM2 (P value for interaction=.007). DM2 was associated with a higher risk of all-cause mortality in women (HR, 1.77; 95%CI, 1.41-2.21; P<.001) but not in men (HR, 1.23; 95%CI, 0.94-1.61; P=.127). CONCLUSIONS: After an episode of acute HF in HFpEF patients, DM2 confers a higher risk of mortality in women. Further studies evaluating the impact of DM2 in women with HFpEF are warranted


Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Diabetes Mellitus Tipo 2/complicações , Insuficiência Cardíaca/complicações , Volume Sistólico/fisiologia , Distribuição por Sexo , Prognóstico , Doença Aguda/mortalidade , Insuficiência Cardíaca/mortalidade , Estudos Prospectivos
5.
Clin Cardiol ; 43(5): 423-429, 2020 May.
Artigo em Inglês | MEDLINE | ID: mdl-32073676

RESUMO

BACKGROUND: The pathophysiology of heart failure with preserved ejection fraction (HFpEF) is complex and multifactorial. Chronotropic incompetence (ChI) has emerged as a crucial pathophysiological mechanism. Beta-blockers, drugs with negative chronotropic effects, are commonly used in HFpEF, although current evidence does not support its routine use in these patients. HYPOTHESIS: We postulate beta-blockers may have deleterious effects in HFpEF and ChI. This work aims to evaluate the short-term effect of beta-blockers withdrawal on functional capacity assessed by the maximal oxygen uptake (peakVO2) in patients with HFpEF and ChI. METHODS: This is a prospective, crossover, randomized (1:1) and multicenter study. After randomization, the clinical and cardiac rhythm will be continuously registered for 30 days. PeakVO2 is assessed by cardiopulmonary exercise testing (CPET) at 15 and 30 days in both groups. Secondary endpoints include quality of life, cognitive, and safety assessment. Patients with stable HFpEF, functional class New York Heart Association (NYHA) II-III, chronic treatment with beta-blockers, and ChI will be enrolled. A sample size estimation [alfa: 0.05, power: 90%, a 20% loss rate, and delta change of mean peakVO2: +1.2 mL/kg/min (SD ± 2.0)] of 52 patients is necessary to test our hypothesis. RESULTS: Patients started enrolling in October 2018. As January 14th, 2020, 28 patients have been enrolled. It is projected to enroll the last patient at the end of July 2020. CONCLUSIONS: Optimizing therapy that improves functional capacity remains an unmeet priority in HFpEF. Deprescribing beta-blockers in patients with HFpEF and ChI seems a plausible intervention to improve functional capacity. This trial is an attempt towards precision medicine in this complex syndrome. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03871803.

6.
Rev Esp Cardiol (Engl Ed) ; 73(6): 463-470, 2020 Jun.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-31629690

RESUMO

INTRODUCTION AND OBJECTIVES: Type 2 diabetes mellitus (DM2) is a common comorbidity in patients with heart failure (HF) with preserved ejection fraction (HFpEF). Previous studies have shown that diabetic women are at higher risk of developing HF than men. However, the long-term prognosis of diabetic HFpEF patients by sex has not been extensively explored. In this study, we aimed to evaluate the differential impact of DM2 on all-cause mortality in men vs women with HFpEF after admission for acute HF. METHODS: We prospectively included 1019 consecutive HFpEF patients discharged after admission for acute HF in a single tertiary referral hospital. Multivariate Cox regression analysis was used to evaluate the interaction between sex and DM2 regarding the risk of long-term all-cause mortality. Risk estimates were calculated as hazard ratios (HR). RESULTS: The mean age of the cohort was 75.6±9.5 years and 609 (59.8%) were women. The proportion of DM2 was similar between sexes (45.1% vs 49.1, P=.211). At a median (interquartile range) follow-up of 3.6 (1-4-6.8) years, 646 (63.4%) patients died. After adjustment for risk factors, comorbidities, biomarkers, echo parameters and treatment at discharge, multivariate analysis showed a differential prognostic effect of DM2 (P value for interaction=.007). DM2 was associated with a higher risk of all-cause mortality in women (HR, 1.77; 95%CI, 1.41-2.21; P <.001) but not in men (HR, 1.23; 95%CI, 0.94-1.61; P=.127). CONCLUSIONS: After an episode of acute HF in HFpEF patients, DM2 confers a higher risk of mortality in women. Further studies evaluating the impact of DM2 in women with HFpEF are warranted.

7.
ESC Heart Fail ; 6(5): 921-926, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-31325239

RESUMO

Women represent nearly half of the adult heart failure (HF) population and they remain underrepresented in HF studies. We aimed to evaluate the evidence about peak oxygen uptake (peak VO2 ) for clinical stratification in women with HF. This narrative review summarizes (i) the evidence endorsing the value of cardiopulmonary exercise testing for clinical stratification and phenotyping HF population; (ii) the determinants of a person's functional aerobic capacity to understand predicted values for patients with chronic HF; and (iii) sex differences on peak VO2 data in different forms of HF. Lastly, based on existing data in patients with HF, we provide a perspective on how to improve existing gaps about the utility of peak VO2 in clinical stratification in women. Peak VO2 provides prognosis information in patients with HF; however, its use has been limited for a reduced number of patients excluding women, elderly, and HF patients with preserved ejection fraction. Further studies will help to fill the wide gender gap about the utility of cardiopulmonary exercise testing in the risk assessment and management in women with HF.


Assuntos
Insuficiência Cardíaca/metabolismo , Consumo de Oxigênio/fisiologia , Oxigênio/metabolismo , Caracteres Sexuais , Adulto , Idoso , Idoso de 80 Anos ou mais , Teste de Esforço/métodos , Tolerância ao Exercício/fisiologia , Feminino , Insuficiência Cardíaca/epidemiologia , Insuficiência Cardíaca/mortalidade , Insuficiência Cardíaca/fisiopatologia , Humanos , Pessoa de Meia-Idade , Fenótipo , Prognóstico , Medição de Risco , Volume Sistólico/fisiologia
8.
Eur J Cardiovasc Nurs ; 18(7): 621-627, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-31148459

RESUMO

BACKGROUND: Heart failure with preserved ejection fraction is a clinical syndrome characterised by reduced exercise capacity. Some evidence has shown that a simple and home-based programme of inspiratory muscle training offers promising results in terms of aerobic capacity improvement in patients with heart failure with preserved ejection fraction. This study aimed to investigate whether the baseline inspiratory muscle function predicts the changes in aerobic capacity (measured as peak oxygen uptake; peak VO2) after a 12-week home-based programme of inspiratory muscle training in patients with heart failure with preserved ejection fraction. METHODS: A total of 45 stable symptomatic patients with heart failure with preserved ejection fraction and New York Heart Association II-III received a 12-week home-based programme of inspiratory muscle training between June 2015 and December 2016. They underwent cardiopulmonary exercise testing and measurements of maximum inspiratory pressure pre and post-inspiratory muscle training. Maximum inspiratory pressure and peak VO2 were registered in both visits. Multivariate linear regression analysis was used to assess the association between changes in peak VO2 (Δ-peakVO2) and baseline predicted maximum inspiratory pressure (pp-MIP). RESULTS: The median (interquartile range) age was 73 (68-77) years, 47% were women and 35.6% displayed New York Heart Association III. The mean peak VO2 at baseline and Δ-peakVO2 post-training were 10.4±2.8 ml/min/kg and +2.2±1.3 ml/min/kg (+21.3%), respectively. The median (interquartile range) of pp-MIP and Δ-MIP were 71% (64-92) and 39.2 (26.7-80.4) cmH2O, respectively. After a multivariate analysis, baseline pp-MIP was not associated with Δ-peakVO2 (ß coefficient 0.005, 95% confidence interval -0.009-0.019, P=0.452). CONCLUSIONS: In symptomatic and deconditioned older patients with heart failure with preserved ejection fraction, a home-based inspiratory muscle training programme improves aerobic capacity regardless of the baseline maximum inspiratory pressure.


Assuntos
Exercícios Respiratórios/métodos , Tolerância ao Exercício/fisiologia , Insuficiência Cardíaca/reabilitação , Contração Muscular/fisiologia , Enfermagem em Reabilitação/métodos , Volume Sistólico/fisiologia , Idoso , Feminino , Humanos , Masculino
9.
Rev. esp. cardiol. (Ed. impr.) ; 72(4): 288-297, abr. 2019. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-187894

RESUMO

Introducción y objetivos: No se dispone de tratamientos farmacológicos que demuestren reducir la morbimortalidad asociada en pacientes con insuficiencia cardiaca y función sistólica conservada (IC-FEc). El objetivo del presente estudio fue evaluar si en pacientes con IC-FEc, el entrenamiento de la musculatura inspiratoria (EMI), la electroestimulación muscular funcional (EMF) o la combinación de ambas (EMI + EMF) puede mejorar la capacidad funcional, calidad de vida, parámetros de disfunción diastólica o biomarcadores a las 12 y 24 semanas. Métodos: Un total de 61 pacientes estables con IC-FEc (clase funcional de la New York Heart Association II-III) se aleatorizaron (1:1:1:1) a recibir un programa de 12 semanas de EMI, EMF, o EMI + EMF frente a tratamiento médico estándar (control). El objetivo primario fue evaluar el cambio en el consumo máximo de oxígeno. Los objetivos secundarios fueron los cambios en la calidad de vida, parámetros ecocardiográficos y biomarcadores. Se utilizó un modelo lineal mixto para comparar los cambios entre los diferentes grupos. Resultados: La edad media fue 74 +/- 9 años y la proporción de mujeres fue del 58%. El test de consumo máximo de oxígeno fue de 9,9 +/- 2,5ml/min/kg. A las 12 semanas, con respecto al grupo control, el incremento medio de consumo máximo de oxígeno fue de 2,98, 2,93 y 2,47 para EMI, EMF y EMI + EMF, respectivamente (p < 0,001). Este incremento se mantuvo a las 24 semanas (1,95, 2,08 y 1,56, respectivamente; p < 0,001). Resultados similares se observaron en la puntuación del cuestionario de calidad de vida (p < 0,001). Conclusiones: En los pacientes con IC-FEc e importante reducción de la capacidad funcional, tanto el EMI como la EMF se asocian con una marcada mejoría de la capacidad funcional y la calidad de vida


Introduction and objectives: Despite the prevalence of heart failure with preserved ejection fraction (HFpEF), there is currently no evidence-based effective therapy for this disease. This study sought to evaluate whether inspiratory muscle training (IMT), functional electrical stimulation (FES), or a combination of both (IMT + FES) improves 12- and 24-week exercise capacity as well as left ventricular diastolic function, biomarker profile, and quality of life in HFpEF. Methods: A total of 61 stable symptomatic patients (New York Heart Association functional class II-III) with HFpEF were randomized (1:1:1:1) to receive a 12-week program of IMT, FES, or IMT + FES vs usual care. The primary endpoint of the study was to evaluate change in peak exercise oxygen uptake at 12 and 24 weeks. Secondary endpoints were changes in quality of life, echocardiogram parameters, and prognostic biomarkers. We used a mixed-effects model for repeated-measures to compare endpoints changes. Results: Mean age and peak exercise oxygen uptake were 74 +/- 9 years and 9.9 +/- 2.5mL/min/kg, respectively. The proportion of women was 58%. At 12 weeks, the mean increase in peak exercise oxygen uptake (mL/kg/min) compared with usual care was 2.98, 2.93, and 2.47 for IMT, FES, and IMT + FES, respectively (P < .001) and this beneficial effect persisted after 24 weeks (1.95, 2.08, and 1.56; P < .001). Significant increases in quality of life scores were found at 12 weeks (P < .001). No other changes were found. Conclusions: In HFpEF patients with low aerobic capacity, IMT and FES were associated with a significant improvement in exercise capacity and quality of life


Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Capacidade Inspiratória/fisiologia , Exercícios Respiratórios/métodos , Estimulação Cardíaca Artificial/métodos , Insuficiência Cardíaca/terapia , Músculos Respiratórios/fisiologia , Indicadores de Morbimortalidade , Biomarcadores/análise , Volume Sistólico/fisiologia
10.
Educ. med. (Ed. impr.) ; 20(supl.1): 37-41, mar. 2019. tab
Artigo em Espanhol | IBECS | ID: ibc-192856

RESUMO

ANTECEDENTES: La enseñanza clínica en la educación médica tiene una particularidad única: el contexto clínico. Este estudio tiene como objetivo analizar las principales barreras de la enseñanza clínica en una facultad joven de Medicina de España. MÉTODOS: Se trata de un estudio transversal descriptivo en el que se solicitó a todos los profesores clínicos (todos ellos profesores asociados) de una facultad joven de Medicina que respondieran a un cuestionario en línea, anónimo y voluntario sobre aspectos de carga asistencial, promoción de la investigación clínica y reconocimiento de sus carreras profesionales. RESULTADOS: Sesenta y un profesores (42%) respondieron al cuestionario. Los principales hallazgos que se obtuvieron fueron: 1) la falta de tiempo protegido para la enseñanza práctica en la institución sanitaria; 2) el escaso apoyo para la investigación clínica por parte de la institución sanitaria o de la facultad; y 3) el escaso de reconocimiento de la carrera profesional. CONCLUSIONES: La enseñanza clínica en la educación médica es un desafío continuo para el clínico. Son necesarios futuros estudios que analicen estos aspectos de forma más exhaustiva


BACKGROUND: There is a unique particularity of clinical teaching in medical education that is beyond knowledge, skills or teaching methods of each clinician: this is clinical teaching context. This study aimed to analyze the main barriers in clinical teaching in a single medical school in Spain. METHODS: This was a descriptive study in which all the clinical teachers (all of them associate professors) of a single and novel faculty of medicine were asked to answer an online, anonymous and voluntary questionnaire about aspects of support to clinical work, promotion of clinical research and recognition of their professional careers. The questionnaires were organized and analyzed into these three main issues. RESULTS: 61 clinical teachers (42%) answered the questionnaire. The main findings that emerged were: (I) lack of protected time for practical teaching at hospital; (II) lack of support for clinical research from hospital or faculty; and (III) lack of recognition of their professional careers. CONCLUSIONS: The clinical teaching in medical education is a continuing challenge for busy clinicians. Further studies on this topic are needed


Assuntos
Humanos , Docentes de Medicina/educação , Docentes de Medicina/normas , Educação Médica/normas , Faculdades de Medicina/estatística & dados numéricos , Estudos Transversais , Pesquisa Biomédica , Inquéritos e Questionários , Acreditação
13.
Rev Esp Cardiol (Engl Ed) ; 72(4): 288-297, 2019 Apr.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-29551699

RESUMO

INTRODUCTION AND OBJECTIVES: Despite the prevalence of heart failure with preserved ejection fraction (HFpEF), there is currently no evidence-based effective therapy for this disease. This study sought to evaluate whether inspiratory muscle training (IMT), functional electrical stimulation (FES), or a combination of both (IMT + FES) improves 12- and 24-week exercise capacity as well as left ventricular diastolic function, biomarker profile, and quality of life in HFpEF. METHODS: A total of 61 stable symptomatic patients (New York Heart Association II-III) with HFpEF were randomized (1:1:1:1) to receive a 12-week program of IMT, FES, or IMT + FES vs usual care. The primary endpoint of the study was to evaluate change in peak exercise oxygen uptake at 12 and 24 weeks. Secondary endpoints were changes in quality of life, echocardiogram parameters, and prognostic biomarkers. We used a mixed-effects model for repeated-measures to compare endpoints changes. RESULTS: Mean age and peak exercise oxygen uptake were 74 ± 9 years and 9.9 ± 2.5mL/min/kg, respectively. The proportion of women was 58%. At 12 weeks, the mean increase in peak exercise oxygen uptake (mL/kg/min) compared with usual care was 2.98, 2.93, and 2.47 for IMT, FES, and IMT + FES, respectively (P < .001) and this beneficial effect persisted after 6 months (1.95, 2.08, and 1.56; P < .001). Significant increases in quality of life scores were found at 12 weeks (P < .001). No other changes were found. CONCLUSIONS: In HFpEF patients with low aerobic capacity, IMT and FES were associated with a significant improvement in exercise capacity and quality of life. This trial was registered at ClinicalTrials.gov (Identifier: NCT02638961)..


Assuntos
Exercícios Respiratórios/métodos , Terapia por Estimulação Elétrica/métodos , Insuficiência Cardíaca/terapia , Assistência ao Convalescente , Idoso , Terapia Combinada , Ecocardiografia , Tolerância ao Exercício/fisiologia , Feminino , Insuficiência Cardíaca/diagnóstico por imagem , Insuficiência Cardíaca/fisiopatologia , Humanos , Masculino , Consumo de Oxigênio/fisiologia , Tamanho da Amostra , Volume Sistólico/fisiologia , Inquéritos e Questionários , Resultado do Tratamento
14.
Clin Cardiol ; 41(4): 476-480, 2018 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-29663436

RESUMO

BACKGROUND: Sodium-glucose linked transporter 2 inhibition recently emerged as a promising therapy for reducing the risk of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). However, there is a lack of data endorsing its role in symptomatic HF patients. We sought to evaluate the short-term effects of empagliflozin on maximal exercise capacity in these patients. HYPOTHESIS: We postulate tretament with empagliflozin may improve functional capacity in patients with T2DM and established HF. METHODS: Nineteen T2DM patients with symptomatic HF were prospectively included and underwent cardiopulmonary exercise testing before and 30 days after initiation of empagliflozin therapy. A mixed-effects model for repeated measures was used. RESULTS: Median patient age was 72 years (interquartile range, 60-79 years); 42.1% were in New York Heart Association class III. Baseline mean (± SD) peak oxygen consumption (peak VO2 ) was 10.9 ± 4.0 mL/min/kg. Peak VO2 increased significantly at 30 days (∆: +1.21 [0.66 to 1.76] mL/min/kg; P < 0.001). A significant improvement in ventilatory efficiency during exercise, 6-minute walking distance, and quality of life, and a reduction in antigen carbohydrate 125, were also found. Estimated glomerular filtration rate and natriuretic peptides did not significantly change. CONCLUSIONS: In this pilot study, empagliflozin was associated with 1-month improvement in exercise capacity in T2DM patients with symptomatic HF. This beneficial effect was also found for other surrogates of severity.


Assuntos
Compostos Benzidrílicos/uso terapêutico , Diabetes Mellitus Tipo 2/tratamento farmacológico , Tolerância ao Exercício/efeitos dos fármacos , Glucosídeos/uso terapêutico , Insuficiência Cardíaca/tratamento farmacológico , Hipoglicemiantes/uso terapêutico , Idoso , Compostos Benzidrílicos/efeitos adversos , Diabetes Mellitus Tipo 2/complicações , Diabetes Mellitus Tipo 2/diagnóstico , Diabetes Mellitus Tipo 2/fisiopatologia , Feminino , Glucosídeos/efeitos adversos , Insuficiência Cardíaca/complicações , Insuficiência Cardíaca/diagnóstico , Insuficiência Cardíaca/fisiopatologia , Humanos , Hipoglicemiantes/efeitos adversos , Masculino , Pessoa de Meia-Idade , Consumo de Oxigênio/efeitos dos fármacos , Projetos Piloto , Estudos Prospectivos , Ventilação Pulmonar/efeitos dos fármacos , Qualidade de Vida , Recuperação de Função Fisiológica , Fatores de Tempo , Resultado do Tratamento , Teste de Caminhada
15.
Rev. esp. cardiol. (Ed. impr.) ; 71(4): 250-256, abr. 2018. tab, ilus, graf
Artigo em Espanhol | IBECS | ID: ibc-171752

RESUMO

Introducción y objetivos. La insuficiencia cardiaca con fracción de eyección conservada (IC-FEc) es un síndrome muy prevalente con alto riesgo de morbilidad y mortalidad. Hasta la fecha, la evidencia acerca del papel del consumo máximo de oxígeno (VO2máx) para predecir la carga de morbilidad en la IC-FEc es escasa. El objetivo de este estudio es evaluar la relación entre el VO2máx y el riesgo de ingresos recurrentes de los pacientes con IC-FEc. Métodos. A un total de 74 pacientes con IC-FEc sintomáticos y clínicamente estables, se les realizó una prueba de esfuerzo cardiopulmonar entre junio de 2012 y mayo de 2016. Se utilizó el método de regresión binomial negativa para determinar la asociación entre el porcentaje de VO2máx predicho (%VO2máx-p) y los ingresos recurrentes. Las estimaciones del riesgo se informaron como tasas de incidencia. Resultados. La media de edad era 72,5 ± 9,1 años, el 53% eran mujeres y todos los pacientes estaban en clase funcional II-III de la New York Heart Association. La media de VO2máx y la mediana de %VO2máx-p fueron 10 ± 2,8 ml/min/kg y el 60% (47-67) respectivamente. Durante un seguimiento medio de 276 [intervalo intercuartílico, 153-1.231] días, se registraron 84 hospitalizaciones por cualquier causa de 31 pacientes (41,9%). También se determinó un total de 15 muertes (20,3%). En un análisis multivariable, teniendo en cuenta la mortalidad como evento terminal, el %VO2máx-p mantuvo la asociación independiente y lineal con el riesgo de ingresos recurrentes. Así, y modelado como continuo, una disminución del 10% del %VO2máx-p aumentó en un 32% el riesgo de ingresos recurrentes (IRR = 1,32; IC95%, 1,03-1,68; p = 0,028). Conclusiones. En los pacientes de edad avanzada con IC-FEc sintomáticos, el %VO2máx-p predice los ingresos recurrentes por todas las causa (AU)


Introduction and objectives. Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent syndrome with an elevated risk of morbidity and mortality. To date, there is scarce evidence on the role of peak exercise oxygen uptake (peak VO2) for predicting the morbidity burden in HFpEF. We sought to evaluate the association between peak VO2 and the risk of recurrent hospitalizations in patients with HFpEF. Methods. A total of 74 stable symptomatic patients with HFpEF underwent a cardiopulmonary exercise test between June 2012 and May 2016. A negative binomial regression method was used to determine the association between the percentage of predicted peak VO2 (pp-peak VO2) and recurrent hospitalizations. Risk estimates are reported as incidence rate ratios. Results. The mean age was 72.5 ± 9.1 years, 53% were women, and all patients were in New York Heart Association functional class II to III. Mean peak VO2 and median pp-peak VO2 were 10 ± 2.8 mL/min/kg and 60% (range, 47-67), respectively. During a median follow-up of 276 days [interquartile range, 153-1231], 84 all-cause hospitalizations in 31 patients (41.9%) were registered. A total of 15 (20.3%) deaths were also recorded. On multivariate analysis, accounting for mortality as a terminal event, pp-peak VO2 was independently and linearly associated with the risk of recurrent admission. Thus, and modeled as continuous, a 10% decrease of pp-peak VO2 increased the risk of recurrent hospitalizations by 32% (IRR, 1.32; 95%CI, 1.03-1.68; P = .028). Conclusions. In symptomatic elderly patients with HFpEF, pp-peak VO2 predicts all-cause recurrent admission (AU)


Assuntos
Humanos , Volume Sistólico/fisiologia , Insuficiência Cardíaca/diagnóstico , Fluxo Expiratório Máximo/fisiologia , Oximetria , Hospitalização/estatística & dados numéricos , Prognóstico , Estudos Prospectivos , Teste de Esforço/estatística & dados numéricos
17.
ESC Heart Fail ; 5(4): 579-585, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-29573575

RESUMO

AIMS: The mechanisms of exercise intolerance in heart failure with preserved ejection fraction (HFpEF) are not yet elucidated. Chronotropic incompetence has emerged as a potential mechanism. We aimed to evaluate whether heart rate (HR) response to exercise is associated to functional capacity in patients with symptomatic HFpEF. METHODS AND RESULTS: We prospectively studied 74 HFpEF patients [35.1% New York Heart Association Class III, 53% female, age (mean ± standard deviation) 72.5 ± 9.1 years, and 59.5% atrial fibrillation]. Functional performance was assessed by peak oxygen consumption (peak VO2 ). The mean (standard deviation) peak VO2 was 10 ± 2.8 mL/min/kg. The following chronotropic parameters were calculated: Delta-HR (HR at peak exercise - HR at rest), chronotropic index (CI) = (HR at peak exercise - resting HR)/[(220 - age) - resting HR], and CI according to the equation developed by Keteyian et al. (CIK) (HR at peak exercise - HR at rest)/[119 + (HR at rest/2) - (age/2) - 5 - HR at rest]. In a bivariate setting, peak VO2 was positively and significantly correlated with Delta-HR (r = 0.35, P = 0.003), CI (r = 0.27, P = 0.022), CIK (r = 0.28, P = 0.018), and borderline with HR at peak exercise (r = 0.22, P = 0.055). In a multivariable linear regression analysis that included clinical, analytical, echocardiographic, and functional capacity covariates, the chronotropic parameters were positively associated with peak VO2 . We found a linear relationship between Delta-HR and peak VO2 (ß coefficient of 0.03; 95% confidence interval: 0.004-0.05; P = 0.030); conversely, the association among CIs and peak VO2 was exponentially shaped. CONCLUSIONS: In patients with chronic HFpEF, the HR response to exercise was positively associated to patient's functional capacity.


Assuntos
Tolerância ao Exercício/fisiologia , Insuficiência Cardíaca/fisiopatologia , Frequência Cardíaca/fisiologia , Volume Sistólico/fisiologia , Idoso , Ecocardiografia , Teste de Esforço , Feminino , Insuficiência Cardíaca/diagnóstico , Humanos , Masculino , Consumo de Oxigênio/fisiologia , Estudos Prospectivos
18.
Rev Esp Cardiol (Engl Ed) ; 71(4): 250-256, 2018 Apr.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-28666951

RESUMO

INTRODUCTION AND OBJECTIVES: Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent syndrome with an elevated risk of morbidity and mortality. To date, there is scarce evidence on the role of peak exercise oxygen uptake (peak VO2) for predicting the morbidity burden in HFpEF. We sought to evaluate the association between peak VO2 and the risk of recurrent hospitalizations in patients with HFpEF. METHODS: A total of 74 stable symptomatic patients with HFpEF underwent a cardiopulmonary exercise test between June 2012 and May 2016. A negative binomial regression method was used to determine the association between the percentage of predicted peak VO2 (pp-peak VO2) and recurrent hospitalizations. Risk estimates are reported as incidence rate ratios. RESULTS: The mean age was 72.5 ± 9.1 years, 53% were women, and all patients were in New York Heart Association functional class II to III. Mean peak VO2 and median pp-peak VO2 were 10 ± 2.8mL/min/kg and 60% (range, 47-67), respectively. During a median follow-up of 276 days [interquartile range, 153-1231], 84 all-cause hospitalizations in 31 patients (41.9%) were registered. A total of 15 (20.3%) deaths were also recorded. On multivariate analysis, accounting for mortality as a terminal event, pp-peak VO2 was independently and linearly associated with the risk of recurrent admission. Thus, and modeled as continuous, a 10% decrease of pp-peak VO2 increased the risk of recurrent hospitalizations by 32% (IRR, 1.32; 95%CI, 1.03-1.68; P = .028). CONCLUSIONS: In symptomatic elderly patients with HFpEF, pp-peak VO2 predicts all-cause recurrent admission.


Assuntos
Exercício Físico/fisiologia , Insuficiência Cardíaca/fisiopatologia , Consumo de Oxigênio/fisiologia , Idoso , Teste de Esforço/métodos , Feminino , Insuficiência Cardíaca/mortalidade , Hospitalização/estatística & dados numéricos , Humanos , Masculino , Estudos Prospectivos , Recidiva , Volume Sistólico/fisiologia
20.
Int J Cardiol ; 252: 136-139, 2018 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-29249422

RESUMO

BACKGROUND: Impaired exercise capacity is the most disabling symptom in patients with heart failure with reduced ejection fraction (HFrEF). Despite sacubitril/valsartan showing reduced long-term morbidity and mortality over enalapril in HFrEF, its effects on short-term functional capacity remain uncertain. We sought to evaluate the effects of sacubitril/valsartan on a 30-day six-minute walk test in eligible patients with HFrEF. METHODS AND RESULTS: From November 1, 2016 to February 1, 2017, a total of 58 stable symptomatic patients with HFrEF were eligible for sacubitril/valsartan and underwent 6-MWT before and 30days after initiation of sacubitril/valsartan therapy. A mixed-effects model for repeated-measures was used to analyze the changes. Mean age was 70±11years. 72.4% males, 46.6% with ischemic heart disease, and 51.7% on NYHA functional class III were included. The mean (SD) values of baseline LVEF and 6MWT were 30±7%, and 300±89m, respectively. The median (IQR) of NT-proBNP at baseline was 2701pg/ml (1087-4200). Compared with baseline, the 6-MWT distance increased significantly at 30days by 13.9% (+∆=41.8m (33.4-50.2); p<0.001). CONCLUSIONS: In this pilot study, sacubitril/valsartan was associated with an improvement in exercise tolerance in symptomatic patients with HFrEF.


Assuntos
Aminobutiratos/farmacologia , Antagonistas de Receptores de Angiotensina/farmacologia , Tolerância ao Exercício/efeitos dos fármacos , Tetrazóis/farmacologia , Teste de Caminhada/tendências , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Combinação de Medicamentos , Eletrocardiografia/efeitos dos fármacos , Eletrocardiografia/tendências , Tolerância ao Exercício/fisiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Estudos Prospectivos , Fatores de Tempo , Resultado do Tratamento , Teste de Caminhada/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...